Dr. Barber on Surgical Readmission and Survival in Ovarian Cancer

Emma Barber, MD
Published Online: Sunday, Mar 12, 2017



Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses surgical readmission and survival in patients with ovarian cancer.

There has been a big push to decrease readmissions to hospitals for patients due to the Affordable Care Act, explains Barber. This is challenging for patients with ovarian cancer due to the difference between short-term and long-term morbidity.

Aggressive surgery for these patients is associated with more complications but long-term outcomes. Neoadjuvant chemotherapy has been shown to decrease surgical morbidity, lowering the complication rates and risk of death.
 


Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses surgical readmission and survival in patients with ovarian cancer.

There has been a big push to decrease readmissions to hospitals for patients due to the Affordable Care Act, explains Barber. This is challenging for patients with ovarian cancer due to the difference between short-term and long-term morbidity.

Aggressive surgery for these patients is associated with more complications but long-term outcomes. Neoadjuvant chemotherapy has been shown to decrease surgical morbidity, lowering the complication rates and risk of death.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire<sup>®</sup>: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication